Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

@article{Pierga2013CirculatingTC,
  title={Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.},
  author={J. Y. Pierga and François-Cl{\'e}ment Bidard and Claire Cropet and Patricia Tresca and Florence Dalenc and Gilles H Romieu and Mario Campone and C Mahier A{\"i}t-Oukhatar and Emilie Le Rhun and Anthony Gonçalv{\`e}s and Marianne Leheurteur and Julien D{\^o}mont and Maya Gutierrez and Herv{\'e} D Cur{\'e} and J. -M. Ferrero and Catherine Labb{\'e}-Devilliers and Thomas Bachelot},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2013},
  volume={24 12},
  pages={2999-3004}
}
BACKGROUND Decrease of circulating tumor cells (CTC) during treatment is an independent prognostic factor in metastatic breast cancer (MBC). We specifically evaluated the impact of CTC on brain metastasis outcome. METHODS HER2-positive MBC with brain metastasis not previously treated with whole-brain radiotherapy received first-line combination of lapatinib and capecitabine in a phase II study. CTC were detected at baseline and day 21 (CellSearch). RESULTS Median follow-up of the 44… CONTINUE READING
Highly Cited
This paper has 110 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

110 Citations

05020142015201620172018
Citations per Year
Semantic Scholar estimates that this publication has 110 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Similar Papers

Loading similar papers…